Clinical Trial: GAVEL: A Clinical Trial With Azacitidine, Venetoclax and Eganelisib (PI3K Gamma Inhibitor) in Acute Myeloid Leukemia

U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07439211) titled 'GAVEL: A Clinical Trial With Azacitidine, Venetoclax and Eganelisib (PI3K Gamma Inhibitor) in Acute Myeloid Leukemia' on Feb. 03.

Brief Summary: This study is to evaluate the safety and preliminary efficacy of adding the PI3K-gamma inhibitor, eganelisib, to a standard of care treatment option with combination venetoclax and azacitidine in participants with acute myeloid leukemia (AML).

The names of the study drugs involved in this research study are:

* Venetoclax (a type of BCL-2 inhibitor)

* Azacitidine (a type of Demethylating Agent)

* Eganelisib (a type of PI3K-gamma inhibitor)

Study Start Date: July, 2026

Study Type: INTER...